Cargando…

A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes

Aside from cell intrinsic factors such as genetic alterations, immune dysregulation in the bone marrow (BM) microenvironment plays a role in the development and progression of myelodysplastic syndromes (MDS). However, the prognostic implications of various immune cells in patients with MDS remain un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yu-Hung, Hou, Hsin-An, Lin, Chien-Chin, Kuo, Yuan-Yeh, Yao, Chi-Yuan, Hsu, Chia-Lang, Tseng, Mei-Hsuan, Tsai, Cheng-Hong, Peng, Yen-Ling, Kao, Chein-Jun, Chou, Wen-Chien, Tien, Hwei-Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Myeloid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759137/ https://www.ncbi.nlm.nih.gov/pubmed/34614508 http://dx.doi.org/10.1182/bloodadvances.2021005141

Ejemplares similares

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2021)

Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA
por: Garcia-Gisbert, Nieves, et al.
Publicado: (2022)

Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies
por: Gorak, Edward J., et al.
Publicado: (2023)

Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis
por: Adrianzen-Herrera, Diego, et al.
Publicado: (2023)

The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression
por: Kfoury, Youmna S., et al.
Publicado: (2023)

Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study
por: Stojkov, Igor, et al.
Publicado: (2023)

Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms
por: Nannya, Yasuhito, et al.
Publicado: (2023)

Higher RUNX1 expression levels are associated with worse overall and leukaemia‐free survival in myelodysplastic syndrome patients
por: Wang, Yu‐Hung, et al.
Publicado: (2022)

ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome
por: West, Robert R., et al.
Publicado: (2022)

Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome
por: Clough, Courtnee A., et al.
Publicado: (2022)

Upregulated SPAG6 promotes acute myeloid leukemia progression through MYO1D that regulates the EGFR family expression
por: Mu, Jiao, et al.
Publicado: (2022)

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
por: Goswami, Swagata, et al.
Publicado: (2022)

A global study for acute myeloid leukemia with RARG rearrangement
por: Zhu, Hong-Hu, et al.
Publicado: (2023)

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
por: Niu, Xiaojia, et al.
Publicado: (2021)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
por: Stengel, Anna, et al.
Publicado: (2021)

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
por: Wakita, Satoshi, et al.
Publicado: (2022)

Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression
por: Stratmann, Svea, et al.
Publicado: (2022)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia
por: Zhao, Lianzhong, et al.
Publicado: (2021)

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

CAMK2G is identified as a novel therapeutic target for myelofibrosis
por: Miyauchi, Masashi, et al.
Publicado: (2022)

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
por: Middeke, Jan M., et al.
Publicado: (2022)

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
por: Fobare, Sydney, et al.
Publicado: (2022)

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
por: Versluis, Jurjen, et al.
Publicado: (2022)

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
por: Weinberg, Olga K., et al.
Publicado: (2022)

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
por: Maslah, Nabih, et al.
Publicado: (2022)

Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome
por: Iijima, Mayuko, et al.
Publicado: (2022)

Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?
por: Brunner, Andrew M., et al.
Publicado: (2022)

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML
por: Martelli, Maria Paola, et al.
Publicado: (2021)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
por: Ramaswamy, Kavitha, et al.
Publicado: (2022)

SORT1/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma
por: Yamamoto, Tomofumi, et al.
Publicado: (2022)

Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia
por: Balasundaram, Nithya, et al.
Publicado: (2022)

The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11
por: Lafage-Pochitaloff, Marina, et al.
Publicado: (2022)

Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2022)

Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
por: Kong, Tim, et al.
Publicado: (2022)

Coping strategies in patients with acute myeloid leukemia
por: Amonoo, Hermioni L., et al.
Publicado: (2022)

Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2(P95H) mutation
por: Xu, Jane Jialu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6m75jrp76snuoqdd1sr9hjj8g9